CD274 and small cell lung carcinoma: In this case, after switching to PD-L1 inhibitor therapy in combination with anlotinib as eighth-line therapy, the patient again benefited with a significant prolongation of PFS for a total of approximately 11 months, which provides clinical evidence for the replacement in SCLC with PD-L1 inhibitors after progression with PD-1 inhibitors.